Nabriva Therapeutics plc (NBRV) reported Q3 EPS of ($4.21), $0.18 worse than the analyst estimate of ($4.03). Revenue for the quarter came in at $9.15 million versus the consensus estimate of $11.05 million.
Nabriva Therapeutics plc (NBRV) reported Q3 EPS of ($4.21), $0.18 worse than the analyst estimate of ($4.03). Revenue for the quarter came in at $9.15 million versus the consensus estimate of $11.05 million.